The hallmark of systemic sclerosis (SSc) is excessive connective tissue accumulation and increased numbers of fibroblasts/myofibroblasts that produce matrix but are refractory to upregulation of matrix metalloproteinase-1 (MMP-1) in the dermis and organs (e.g. lungs) involved in the disease. It has been assumed that the increased numbers of fibroblasts/myofibroblasts present in the fibrogenic lesions of SSc arise from proliferation and growth of local fibroblasts. In addition to this local source for fibroblasts/myofibroblasts in SSc lesions, we present evidence in this proposal that the blood may also be an important source for such cells. We have observed that SSc peripheral blood mononuclear cells (PBMC) when cultured for 5 days with native type l collagen (CI) or constituent alpha chains and then for >21 days gives rise to fibroblast-like cells (FLC) which stain positive for fibroblast and myofibroblast markers, synthesize CI, CIII and hyaluronic acid but do not upregulate MMP-1 in response to inflammatory cytokine stimulation. We believe this observation has major implications for a new understanding of SSc pathogenesis. This project proposes a detailed analysis of the FLC outgrowth phenomenon. It will test the hypothesis in the 1st 2 specific aims that FLC outgrowth from SSc PBMC cultured with CI in vitro is correlated with the degree of cell-mediated immunity to CI and that downregulation of the immune response by oral tolerance induction to CI will be associated with decreased outgrowth of FLC from PBMC cultured with CI. Additional studies will determine whether the degree of immunity to CI in SSc patients and/or modified Rodnan skin score and/or disease duration correlate with degree of outgrowth of FLC from Cl-stimulated PBMC cultures; determine which cytokines/growth factors are associated with FLC outgrowth and whether such identified cytokines/growth factors can trans differentiate PBMC precursors into FLC; identify which alpha1 (l) and alpha(l) l cyanogen bromide peptides induce FLC outgrowth from SSc PBMC; and what is the spectrum of the types of FLC grown from Cl-stimulated SSc PBMC. These studies should provide clues not only to pathogenetic mechanisms of fibroblast accumulation in SSc lesions, but should also provide clues to new therapeutic approaches for treating this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR044890-02
Application #
6659988
Study Section
Special Emphasis Panel (ZAR1)
Project Start
2002-08-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Type
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Atamas, S P; Luzina, I G; Ingels, J et al. (2010) Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). Clin Exp Immunol 161:426-35
Yin, Zhaohong; Carbone, Laura D; Gotoh, Mari et al. (2010) Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford) 49:2290-7
Postlethwaite, Arnold E; Harris, L Jeff; Raza, Syed H et al. (2010) Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother 11:789-806
Chiang, Thomas M; Postlethwaite, Arnold E (2008) Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis. Thromb Res 122:501-6
Postlethwaite, Arnold E; Wong, Weng Kee; Clements, Philip et al. (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase di Arthritis Rheum 58:1810-22
Chiang, Thomas M; Postlethwaite, Arnold E (2007) A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta 1770:1181-6
Du, Haiming; Zawaski, Janice A; Gaber, M Waleed et al. (2007) A recombinant protein and a chemically synthesized peptide containing the active peptides of the platelet collagen receptors inhibit ferric chloride-induced thrombosis in a rat model. Thromb Res 121:419-26
Postlethwaite, Arnold E; Chiang, Thomas M (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574-9
Zhu, Jiaqian; Cole, Flecia; Woo-Rasberry, Virginia et al. (2007) Type I and type III collagen-platelet interaction: inhibition by type specific receptor peptides. Thromb Res 119:111-9
Chiang, Thomas M; Postlethwaite, Arnold E (2006) Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta 1760:32-7

Showing the most recent 10 out of 16 publications